Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 3/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.37 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22425886 | 1.00 | GAA (0.43) | GAAALDH1A1AAK1LMNAHTT | |
| SCHEMBL22425936 | 0.82 | GAA (0.43) | GAAALDH1A1AAK1LMNAHTT | |
| SCHEMBL22425939 | 0.82 | PPARA (0.47) | GAAALDH1A1AAK1LMNAHTT | |
| SCHEMBL22425737 | 0.82 | PPARA (0.47) | GAAALDH1A1AAK1LMNAHTT | |
| SCHEMBL22425744 | 0.82 | PPARA (0.47) | GAAALDH1A1AAK1LMNAHTT | |
| SCHEMBL18928696 | 0.77 | ITGA4 (0.56) | PPARAITGA4ITGB7CTSSCTSK | |
| SCHEMBL22425988 | 0.76 | GAA (0.41) | GAAALDH1A1AAK1LMNAHTT | |
| SCHEMBL22412145 | 0.76 | GAA (0.41) | GAAALDH1A1AAK1LMNAHTT | |
| SCHEMBL31172068 | 0.76 | GAA (0.41) | GAAALDH1A1AAK1LMNAHTT | |
| SCHEMBL6681923 | 0.75 | ALDH1A1 (0.52) | GAAALDH1A1LMNAHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177486-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. | 2022-06-09 | — | — | US | disclosed |
| WO-2020185755-A1 | TYK2 INHIBITORS AND USES THEREOF | FRONTHERA U.S. PHARMACEUTICALS LLC (US) | 2020-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177486-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | GAA 3318/4885ALDH1A1 4098/4885AAK1 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.